Document is current
Any future updates will be listed below
-
Authors
Ruiz de Sabando, Ainara https://orcid.org/0000-0003-3634-465X
Ciosi, Marc
Galbete, Arkaitz
Cumming, Sarah A. https://orcid.org/0000-0002-0201-3660
,
Álvarez, Victoria
Martinez-Descals, Asunción
Mila, Montserrat
Trujillo-Tiebas, Maria José
López-Sendón, Jose Luis
Fenollar-Cortés, María
Legarda, Inés
Bernal Noguera, Sara
Millán, Jose M.
Durán-Herrera, Camen
Ruiz-Martínez, Javier
Ruiz Onandi, Rebeca
Monckton, Darren G. https://orcid.org/0000-0002-8298-8264
Ramos-Arroyo, Maria A. https://orcid.org/0000-0002-7171-9202
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (FIS PI15/02227)
Enroll-HD Departamento de Salud, Gobierno de Navarra
- License Information
-
More Information
Article History
Received: 16 August 2023
Revised: 8 January 2024
Accepted: 17 January 2024
First Online: 4 March 2024
Competing interests
: Within the last 5 years, DGM has been a scientific consultant and/or received an honoraria/stock options/grants from AMO Pharma, Charles River, LoQus23, Triplet Therapeutics, Ono Pharmaceuticals, Rgenta Therapeutics, Novartis, Dyne and Vertex Pharmaceuticals. DGM also had research contracts with AMO Pharma and Vertex Pharmaceuticals.
: The study was carried out according to the Spanish Biomedical Research Law (Ley 14/2007, de 3 de julio, de Investigación Biomédica) . Participation in the study was approved by all collaborative centres. The study was approved by the Central Ethics Committee of Clinical Research “Comité de Ética de la Investigación con medicamentos (CEIm)” of Gobierno de Navarra (PI_2015/78. Res. 662, 18th October 2019). Written informed consent was obtained from all participants required by the CEIm, and data were deidentified. For individuals of the three HD families studied a specific written consent was signed and archived.
